Anti-Ipilimumab (YERVOY) ELISA Assay Kit
The Anti-Ipilimumab (YERVOY) ELISA Assay Kit is For Research Use Only
Size: 12×8 wells
Sensitivity: +/-
Incubation Time: 2 hours 20 minutes
Sample Type: Serum, Plasma
Sample Size: 20 µl
Alternative Name: Yervoy
Assay Background
ipilimumab is a monoclonal antibody, more specifically a fully humanized IgGl antibody produced in mammalian cell culture, to the cytotoxic T lymphocyte antigen-4 (CTLA-4) which activates antitumor immunity by inhibiting this major checkpoint. The cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a cell surface molecule that plays an essential role in regulating the adaptative immune response. The activation of T-cells is tightly controlled by two main signals l) initial binding of tumor-associated antigens on antigen presenting cells to T-cell receptors and 2) subsequent binding of B7 molecules on the antigen presenting cells to CD28 receptors on T cells. After T-cell activation, CTLA-4 will be upregulated and it will compete on the binding between CD28 and B7. The binding between CTLA-4 and B7 interrupts the stimulatory signal which in order blunts T-cell proliferation response. The action of ipilimumab produces an exacerbated autoimmunity. This is explained as the absence or presence of CTLA-4 can augment or suppress the immune system’s T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining a potent T-cell response against tumor cells.
Assay Principle
Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Controls and samples (serum or plasma) are incubated in the microtiter plate coated with the drug ipilimumab. After incubation, the wells are washed. Then, horse radish peroxidase (HRP) conjugated probe is added and binds to ipilimumab antibodies captured by the drug ipilimumab on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of ipilimumab antibodies in the sample or controls. The results can be evaluated with using cut-off value.
Related Products
Ipilimumab ELISA Assay Kit
Anti-Denosumab ELISA Assay
Anti-Atezolizumab (Tecentriq) ELISA Assay Kit
